CKD Flashcards
1
Q
LEADER trial conclusion
A
Liraglutide was found to reduce all cause mortality and MACE compared to placebo in patients with eGFR <60
2
Q
AWARD 7 trial ( Dulaglutide vs Glargine)
A
Dulaglutide was found to significantly reduce the decline of eGFR in patients with stage 3 and 4 CKD but had no significant effect on ESRD or kidney transplant.
There was also no significant difference in all-cause or cardiovascular mortality, but AWARD-7 was not designed to assess mortality and MACE outcomes.
